NUVA

NuVasive, Inc. [NUVA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NUVA Stock Summary

Top NUVA Correlated Resources

NUVA


Top 10 Correlated ETFs

NUVA


Top 10 Correlated Stocks

NUVA


In the News

12:47 08 Dec 2022 NUVA

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

09:52 08 Dec 2022 NUVA

NuVasive, Inc. (NUVA) Q3 2022 - Earnings Call Transcript

NuVasive, Inc. (NASDAQ:NUVA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Chris Barry - Chief Executive Officer Matt Harbaugh - Chief Financial Officer Conference Call Participants Matt Miksic - Barclays Joshua Jennings - Cowen Vikramjeet Chopra - Wells Fargo Joanne Wuensch - Citibank Samuel Brodovsky - Truist Shagun Singh - RBC David Saxon - Needham & Company Jeffrey Johnson - Baird Matthew Taylor - Jefferies Allen Gong - JPMorgan Matthew O'Brien - Piper Sandler Matthew Blackman - Stifel Operator Good day, ladies and gentlemen, and welcome to the NuVasive Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to introduce your host for today's call, Miss.

06:48 08 Dec 2022 NUVA

NuVasive (NUVA) Surpasses Q3 Earnings Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:37 08 Dec 2022 NUVA

NuVasive: Prepared To Endure Current Headwinds

The share price declined by ~46% since the beginning of the coronavirus pandemic crisis in 2020. Revenues returned to the growth path thanks to high R&D expenses and acquisitions.

07:00 08 Dec 2022 NUVA

NuVasive Announces Conference Call and Webcast of Third Quarter 2022 Results

SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close. NuVasive will hold a conference call on Wednesday, November 9, 2022, at 4:30 p.m.

01:33 08 Dec 2022 NUVA

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

09:37 08 Dec 2022 NUVA

NuVasive, Inc. (NUVA) CEO Chris Barry on Q2 2022 Results - Earnings Call Transcript

NuVasive, Inc. (NASDAQ:NUVA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Juliet Cunningham – Vice President-Investor Relations Chris Barry – Chief Executive Officer Matt Harbaugh – Chief Financial Officer Conference Call Participants Josh Jennings – Cowen Vik Chopra – Wells Fargo Joanne Wuensch – Citi Shagun Singh – RBC Capital Markets Allen Gong – JPMorgan Rich Newitter – Truist Securities Drew Ranieri – Morgan Stanley Jason Wittes – Loop Capital Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the NuVasive Second Quarter 2022 Earnings Conference Call. I would now like to introduce your host for today's call, Ms.

07:33 08 Dec 2022 NUVA

NuVasive (NUVA) Lags Q2 Earnings Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

01:13 08 Dec 2022 NUVA

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

NUVA vs. RMD: Which Stock Is the Better Value Option?

11:18 08 Dec 2022 NUVA

NuVasive (NUVA) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NUVA Financial details

Company Rating
Buy
Market Cap
2.08B
Income
-20.41M
Revenue
1.2B
Book val./share
15.98
Cash/share
4.56
Dividend
-
Dividend %
-
Employees
2.9K
Optionable
No
Shortable
Yes
Earnings
21 Feb 2023
P/E
-55.37
Forward P/E
16.45
PEG
12.38
P/S
1.74
P/B
2.5
P/C
9.09
P/FCF
77.18
Quick Ratio
0.68
Current Ratio
1.21
Debt / Equity
1.2
LT Debt / Equity
1.2
-
-
EPS (TTM)
-0.4
EPS next Y
2.52
EPS next Q
0.64
EPS this Y
72.22%
EPS next Y
-731.91%
EPS next 5Y
-731.91%
EPS last 5Y
NAN%
Revenue last 5Y
2.04%
Revenue Q/Q
-4.89%
EPS Q/Q
90%
-
-
-
-
SMA20
-2.44%
SMA50
-9.09%
SMA100
-20%
Inst Own
100%
Inst Trans
14.51%
ROA
-1%
ROE
-2%
ROC
0.05%
Gross Margin
73%
Oper. Margin
7%
Profit Margin
-2%
Payout
-
Shs Outstand
52.13M
Shs Float
52M
-
-
-
-
Target Price
58
52W Range
35.17-60.47
52W High
-30.92%
52W Low
+18.43%
RSI
55
Rel Volume
0.82
Avg Volume
702.28K
Volume
573.11K
Perf Week
6.72%
Perf Month
-4.16%
Perf Quarter
-14%
Perf Half Y
-19.86%
-
-
-
-
Beta
1.05985
-
-
Volatility
0.73%, 2.44%
Prev Close
3.55%
Price
41.45
Change
7.08%

NUVA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
20.2421.4422.4820.4322.15
Net income per share
1.630.241.26-0.72-1.25
Operating cash flow per share
3.524.274.533.623.54
Free cash flow per share
1.312.132.021.481.36
Cash per share
1.432.294.120.034.79
Book value per share
15.6316.2417.6217.8715.47
Tangible book value per share
-0.360.412.954.03-1.57
Share holders equity per share
15.6316.2417.6217.8715.47
Interest debt per share
12.2112.4614.2531.1519.98
Market cap
2.54B2.5B4.09B2.76B2.55B
Enterprise value
3.05B2.99B4.58B3.44B3.31B
P/E ratio
30.62200.6462.65-74.37-39.79
Price to sales ratio
2.472.273.52.632.24
POCF ratio
14.211.4217.3714.8614
PFCF ratio
38.2322.8538.9636.236.58
P/B Ratio
3.234.473.013.21
PTB ratio
3.234.473.013.21
EV to sales
2.962.713.923.272.91
Enterprise value over EBITDA
12.9816.9517.9720.9829.51
EV to operating cash flow
17.0513.6319.4518.4918.17
EV to free cash flow
45.927.2743.6245.0447.49
Earnings yield
0.0300.02-0.01-0.03
Free cash flow yield
0.030.040.030.030.03
Debt to equity
0.730.720.760.961.25
Debt to assets
0.510.510.510.660.63
Net debt to EBITDA
2.172.751.924.116.78
Current ratio
3.483.443.691.873.99
Interest coverage
3.212.73.140.712.69
Income quality
2.1617.563.61-5-2.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.520.52000
Research and developement to revenue
0.050.060.060.080.08
Intangibles to total assets
0.50.480.40.260.41
Capex to operating cash flow
-0.63-0.5-0.55-0.59-0.62
Capex to revenue
-0.11-0.1-0.11-0.1-0.1
Capex to depreciation
-0.93-0.84-0.96-0.78-0.75
Stock based compensation to revenue
0.020.020.030.020.02
Graham number
23.969.4222.3117.0520.83
ROIC
0.080.070.070.030.03
Return on tangible assets
0.10.010.06-0.02-0.05
Graham Net
-9.71-9.18-8.51-8.53-15.44
Working capital
398.32M438.75M557.42M725.82M601.53M
Tangible asset value
-18.55M21.11M153.05M207.1M-80.94M
Net current asset value
-280.92M-255.13M-205.75M-211.98M-556.44M
Invested capital
0.730.720.771.671.27
Average receivables
203.06M201.78M209.3M207.07M210.73M
Average payables
10.88M13.09M14.61M17.39M16.79M
Average inventory
273.93M286.93M306.52M300.62M308.23M
Days sales outstanding
70.5765.166.171.9468.71
Days payables outstanding
5.9210.3213.8219.7318.34
Days of inventory on hand
335.47320.52365.07341.16357.71
Receivables turnover
5.175.615.525.075.31
Payables turnover
61.6135.3626.4118.519.9
Inventory turnover
1.091.1411.071.02
ROE
0.10.010.07-0.04-0.08
Capex per share
-2.21-2.13-2.51-2.13-2.19

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
5.245.845.615.975.67
Net income per share
-0.42-0.710.37-0.02-0.04
Operating cash flow per share
1.270.720.131.181.04
Free cash flow per share
0.640.23-0.510.50.3
Cash per share
4.544.763.964.344.56
Book value per share
15.9515.3715.6715.8915.98
Tangible book value per share
-1.26-1.56-1.12-0.220.38
Share holders equity per share
15.9515.3715.6715.8915.98
Interest debt per share
19.5519.5419.4919.4127.97
Market cap
3.09B2.72B2.94B2.56B2.28B
Enterprise value
3.86B3.48B3.74B3.34B3.5B
P/E ratio
-35.73-18.4838.26-715.96-288.45
Price to sales ratio
11.428.9910.118.247.73
POCF ratio
47.372.59449.4141.5542.04
PFCF ratio
93.07230.52-110.1398.24143.64
P/B Ratio
3.753.413.623.092.74
PTB ratio
3.753.413.623.092.74
EV to sales
14.2711.5112.8610.7511.84
Enterprise value over EBITDA
212.62426.6457.5183.1487.11
EV to operating cash flow
59.192.92571.8554.2164.43
EV to free cash flow
116.28295.08-140.13128.19220.13
Earnings yield
-0.01-0.010.0100
Free cash flow yield
0.010-0.010.010.01
Debt to equity
1.211.251.230.661.2
Debt to assets
0.610.630.620.620.62
Net debt to EBITDA
42.4593.3412.3119.4230.27
Current ratio
3.943.993.191.171.21
Interest coverage
-0.484.33.425.855
Income quality
-3.02-1.020.34-68.93-27.44
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.090.080.080.080.08
Intangibles to total assets
0.420.410.40.390.37
Capex to operating cash flow
-0.49-0.69-5.08-0.58-0.71
Capex to revenue
-0.12-0.08-0.11-0.11-0.13
Capex to depreciation
-0.85-0.68-0.9-0.97-1.04
Stock based compensation to revenue
0.020.020.020.020.02
Graham number
12.2615.6711.432.483.7
ROIC
00.010.010.020.01
Return on tangible assets
-0.02-0.030.0100
Graham Net
-14.9-15.35-15.58-15.01-14.56
Working capital
575M601.53M543.49M121.95M145.83M
Tangible asset value
-65.34M-80.94M-58.08M-11.64M19.73M
Net current asset value
-539.48M-556.44M-556.37M-524.31M-499.57M
Invested capital
1.221.271.241.221.74
Average receivables
216.47M223.99M232.5M233.57M234.58M
Average payables
117.29M69.99M119.73M123.78M0
Average inventory
321.56M323.78M328.06M331.71M336.35M
Days sales outstanding
66.2563.8871.6367.7171.8
Days payables outstanding
112.4817.45131.62129.90
Days of inventory on hand
316.15340.29369.12348.12379.48
Receivables turnover
1.361.411.261.331.25
Payables turnover
0.85.160.680.690
Inventory turnover
0.280.260.240.260.24
ROE
-0.03-0.050.0200
Capex per share
-0.62-0.5-0.64-0.68-0.74

NUVA Frequently Asked Questions

What is NuVasive, Inc. stock symbol ?

NuVasive, Inc. is a US stock , located in San diego of California and trading under the symbol NUVA

Is NuVasive, Inc. buy or a sell ?

8 stock analysts have 8 predictions with a medium analyst target price of $60.75. The lowest prediction is $50 and the highest is $80

What is NUVA stock prediction ?

With a median analyst target price of $58, 1 stock analysts have made 1 forecasts in last 90 days. $58 is the lowest and $58 is the greatest projection.

What is NuVasive, Inc. stock quote today ?

NuVasive, Inc. stock price is $41.45 today.

Is NuVasive, Inc. stock public?

Yes, NuVasive, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks